Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000228585 | SCV000288345 | likely benign | Neuroblastoma, susceptibility to, 3 | 2024-01-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002450691 | SCV002615515 | likely benign | Hereditary cancer-predisposing syndrome | 2022-03-20 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Breakthrough Genomics, |
RCV004710608 | SCV005263313 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003947778 | SCV004761961 | likely benign | ALK-related disorder | 2020-01-23 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |